HC Wainwright Reiterates “Neutral” Rating for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports.

Separately, Jefferies Financial Group upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and raised their target price for the company from $2.00 to $35.00 in a research report on Friday, September 20th.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock opened at $15.16 on Friday. Assembly Biosciences has a twelve month low of $9.12 and a twelve month high of $19.93. The company’s 50 day moving average is $16.05 and its 200 day moving average is $15.59.

Insider Activity at Assembly Biosciences

In related news, major shareholder Alexander Schornstein purchased 10,000 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, October 8th. The stock was purchased at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the transaction, the insider now directly owns 703,113 shares in the company, valued at approximately $10,251,387.54. This trade represents a 1.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 394 shares of company stock valued at $5,894. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently bought and sold shares of ASMB. JPMorgan Chase & Co. grew its holdings in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 3,442 shares in the last quarter. FMR LLC boosted its position in Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares during the last quarter. Acadian Asset Management LLC grew its stake in Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 7,690 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in Assembly Biosciences in the 2nd quarter worth approximately $6,421,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.